Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Alignment Healthcare (ALHC.O)*

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date Stock Price (US$) Price Target (US$) Rating
2022-01-247.4324.00Neutral
2022-03-049.2911.00Neutral
2022-08-0517.9117.00Neutral
2022-11-0313.4016.00Neutral
2023-02-289.9410.00Neutral
2023-05-047.008.00Neutral
2023-07-135.196.00Neutral
2023-11-036.026.50Neutral
2023-12-218.749.00Neutral
2024-02-285.668.50Neutral
2024-05-025.266.50Neutral
2024-08-028.949.00Neutral
2024-10-2911.7112.00Neutral
2025-02-2713.4716.00Neutral

Disclosures

  • UBS Securities LLC makes a market in the securities and/or ADRs of this company.
  • Because this security exhibits higher-than-average volatility, the FSR has been set at 15% above the MRA for a Buy rating, and at -15% below the MRA for a Sell rating (compared with 6/-6% under the normal rating system).
  • UBS holds a long or short position of 0.5% or more of the listed shares of this company.
Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day. Issuers with an EQ Rating & Price Target Table are covered by UBS-IB Equity Research Analysts. Issuers without an EQ Rating & Price Target Table are not single stock covered.

* Issuers marked with an asterisk are covered by UBS-IB Equity Research Analysts. Issuers without an asterisk are not single stock covered.